Ezt az oldalt automatikusan lefordították, és a fordítás pontossága nem garantált. Kérjük, olvassa el a angol verzió forrásszöveghez.

Immune Response Induced by a Vaccine Against Group B Streptococcus and Safety in Pregnant Women and Their Offsprings

2014. szeptember 5. frissítette: Novartis

A Phase II Randomized, Observer-Blind, Multi-Center, Controlled Study of a Trivalent Group B Streptococcus Vaccine in Healthy Pregnant Women

The study investigated the immune response induced by the Group B streptococcus vaccine in healthy pregnant women. In addition, the study investigated the amount of vaccine induced antibodies which were transferred to the newborn.

A tanulmány áttekintése

Tanulmány típusa

Beavatkozó

Beiratkozás (Tényleges)

86

Fázis

  • 2. fázis

Kapcsolatok és helyek

Ez a rész a vizsgálatot végzők elérhetőségeit, valamint a vizsgálat lefolytatásának helyére vonatkozó információkat tartalmazza.

Tanulmányi helyek

    • Leuven
      • Herestraat, Leuven, Belgium, 49-B-3000
        • UZ Leuven
    • Tienen
      • Gasthuismolenstraat 31, Tienen, Belgium, 3300
        • Regionaal Ziekenhuis Heilig Hart,
    • British Columbia
      • Vancouver, British Columbia, Kanada, V6H3N1
        • University of British Columbia, Rm B3 25 B, 4500 Oak Street,
    • Nova Scotia
      • Halifax, Nova Scotia, Kanada, B3K 6R8
        • Dalhousie University, IWK Health Centre, 5850/5980 University Avenue,
    • Quebec
      • Boulevard laurier, S-745, Quebec, Kanada, G1V 4G2
        • Centre hospitalier universitaire de Quebec (CHUQ)- hospital CHUL, Centre de recherche en infectiologie, 2705,

Részvételi kritériumok

A kutatók olyan embereket keresnek, akik megfelelnek egy bizonyos leírásnak, az úgynevezett jogosultsági kritériumoknak. Néhány példa ezekre a kritériumokra a személy általános egészségi állapota vagy a korábbi kezelések.

Jogosultsági kritériumok

Tanulmányozható életkorok

18 év (Felnőtt)

Egészséges önkénteseket fogad

Igen

Tanulmányozható nemek

Női

Leírás

Inclusion Criteria:

  1. Healthy pregnant women 18-40 years of age at 24-35 weeks of gestation at screening.
  2. Individuals who have given a written consent after the nature of the study has been explained according to local regulatory requirements.
  3. Individuals in good health as determined by the outcome of medical history, physical examination and clinical judgment of the investigator.
  4. Individuals who will be available for all scheduled visits (ie, not planning to leave the area before the end of the study period).

Exclusion Criteria:

  1. Individuals who were unwilling and/or unable to give written informed consent to participate in the study.
  2. Individuals with a history of severe allergic reactions after previous vaccinations such as anaphylactic shock, asthma, urticaria, or other allergic reaction or hypersensitivity to any vaccine component.
  3. Individuals with any known or suspected impairment/alteration of immune function, either congenital or acquired or resulting from:

    • receipt of immunosuppressive therapy within 30 days prior to enrollment (any systemic corticosteroid administered for more than 5 days, or in a daily dose > 15 mg/kg/day prednisone or equivalent during any of 30 days prior to enrollment, or cancer chemotherapy).
    • receipt of immunostimulants.
    • receipt of parenteral immunoglobulin preparation, blood products, and /or plasma derivatives within 12 weeks prior to enrollment and for the full length of the study.

    Note: Anti-D (Rho) Immunoglobulins (anti-RhD) given for Anti-D prophylaxis were to be allowed.

  4. Individuals characterized as "high risk" pregnancies at investigator discretion, such as those who have:

    • gestational diabetes
    • preeclampsia/eclampsia
    • women at risk of preterm labor (except positivity for vaginal GBS)
    • History of previous pregnancy complications including delivery of preterm infant.
    • History of still-birth, late abortions and children with congenital anomalies.
  5. Individuals who had received any other investigational agent or investigational intervention during the course of the study.
  6. Individuals with acute infection including oral temperature ≥ 38°C were to be temporarily excluded. They could be enrolled once the infection had resolved (as judged by investigator).
  7. HIV positive by history.
  8. Individuals reporting any known or suspected serious acute, chronic or progressive disease (eg, any history of neoplasm, malignancy, including lymphoproliferative disorder, diabetes, cardiac disease, malnutrition, renal failure, autoimmune disease, HBV or HCV, blood disorders).

    Note: Malignancies, highly likely to having been cured at the investigators discretion are allowed. (eg, no relapse since 5 years post last malignancy specific treatment).

  9. Individuals with bleeding diathesis, or any condition that might have been associated with a prolonged bleeding time.
  10. Individuals with behavioral or cognitive impairment or psychiatric disease that, in the opinion of the investigator, might have interfered with the subject's ability to participate in the study (eg, who were not able to comprehend or to follow all required study procedures for the whole period of the study).
  11. Individuals with any progressive or severe neurologic disorder, seizure disorder, epilepsy or Guillain-Barré syndrome.
  12. Individuals with history or any illness that, in the opinion of the investigator, might have posed additional risk to subjects due to participation in the study.
  13. Individuals who were part of study personnel or close family members conducting this study.

Tanulási terv

Ez a rész a vizsgálati terv részleteit tartalmazza, beleértve a vizsgálat megtervezését és a vizsgálat mérését.

Hogyan készül a tanulmány?

Tervezési részletek

  • Elsődleges cél: Megelőzés
  • Kiosztás: Véletlenszerűsített
  • Beavatkozó modell: Párhuzamos hozzárendelés
  • Maszkolás: Egyetlen

Fegyverek és beavatkozások

Résztvevő csoport / kar
Beavatkozás / kezelés
Kísérleti: Group B Streptococcus Trivalent Vaccine
Pregnant women who received one injection of Group B Streptococcus Trivalent Vaccine.
Pregnant women who received one injection of Group B Streptococcus Trivalent Vaccine administered intramuscularly.
Placebo Comparator: Placebo
Pregnant women who received one injection of saline solution.
Pregnant women who received one injection of saline solution administered intramuscularly.

Mit mér a tanulmány?

Elsődleges eredményintézkedések

Eredménymérő
Intézkedés leírása
Időkeret
Geometric Mean Concentrations (GMCs) of Antibodies in Mothers and Infants at Delivery/Birth
Időkeret: Day of delivery/birth
GMCs of anti-Group B Streptococcus (GBS) capsular polysaccharide (CPS) antibodies against serotypes Ia, Ib and III in mothers and in infants at delivery/birth are presented.
Day of delivery/birth
Geometric Mean of the Ratios Between Infant Antibody Level (μg/mL) and Maternal Antibody Level (μg/mL) at Time of Delivery
Időkeret: Day of delivery/birth
The Geometric mean transfer ratio of anti-GBS CPS antibodies against serotypes Ia, Ib and III at delivery is calculated as the geometric mean of the pairwise ratios between the antibody concentrations from infant at birth and to maternal serum concentration at delivery.
Day of delivery/birth

Másodlagos eredményintézkedések

Eredménymérő
Intézkedés leírása
Időkeret
GMCs (Enzyme-linked Immunosorbent Assay, ELISA) Antibodies Against Serotypes Ia, Ib and III in Maternal Subjects
Időkeret: Day 1, day 31 and day 91 post-delivery
GMCs (ELISA) of anti-GBS CPS antibodies against serotypes Ia, Ib and III in maternal subjects at study day 1, study day 31 and at day 91 post-partum after one administration of GBS vaccine or placebo are reported.
Day 1, day 31 and day 91 post-delivery
Geometric Mean Ratios (GMRs) of Antibody GMCs (ELISA) in Maternal Subjects
Időkeret: Day 31, day of delivery, day 91 post-delivery
GMRs of GMCs (ELISA) of anti-GBS CPS antibodies against serotypes Ia, Ib and III, in maternal subjects at study day 31, at delivery and at day 91 post-partum versus day 1 (baseline) after one administration of GBS vaccine or placebo are reported.
Day 31, day of delivery, day 91 post-delivery
GMC (ELISA) of Anti-GBS CPS Antibodies in Infants
Időkeret: Day of birth and day 91 after birth
GMC (ELISA) of anti-GBS CPS antibodies against serotypes Ia, Ib and III in infants at birth and at 3 months of age are reported.
Day of birth and day 91 after birth
GMRs of Anti-GBS CPS Antibody GMCs (ELISA) in Infants at 3 Months of Age Versus GMCs at Birth
Időkeret: Day 91 after birth
GMRs of anti-GBS CPS antibody GMCs (ELISA) against serotypes Ia, Ib and III in infants at 3 months of age (day 91 after birth) versus GMCs at birth are reported.
Day 91 after birth
Percentages of Infant Subjects Showing Anti-diphtheria Antibodies GMCs (ELISA) Over 0.1 IU/mL at 1 Month After the Last Routine Infant Immunization
Időkeret: 1 month after the last routine infant immunization
Percentages of infant subjects showing anti-diphtheria antibodies GMCs (ELISA) over 0.1 IU/mL in sera collected at 1 month after the last routine infant immunization (ie, either 5 months or 7 months after birth, depending on the vaccination schedule) are reported.
1 month after the last routine infant immunization
Percentage of Maternal Subjects Reporting Solicited Local and Systemic Adverse Events (AEs)
Időkeret: From day 1 to 7 after vaccination
Percentage of maternal subjects reporting solicited local and systemic AEs and other indicators of reactogenicity from day 1 to 7 after vaccination are reported.
From day 1 to 7 after vaccination
Percentage of Maternal Subjects Reporting Unsolicited AEs and Serious Adverse Events (SAEs)
Időkeret: All AEs were recorded until delivery, after delivery all AEs requiring a non-routine physician's visit and AEs leading to withdrawal from the study. SAEs were collected for the duration of the trial.
Percentage of maternal subjects reporting unsolicited AEs, SAEs, AEs requiring a non-routine physician's visit, AEs leading to withdrawal are reported.
All AEs were recorded until delivery, after delivery all AEs requiring a non-routine physician's visit and AEs leading to withdrawal from the study. SAEs were collected for the duration of the trial.
Percentages of Infants Reporting SAEs
Időkeret: From birth until study termination
Percentages of infants born from women who received either one injection of the study vaccine or placebo, reporting SAEs from birth until study termination are reported.
From birth until study termination

Együttműködők és nyomozók

Itt találhatja meg a tanulmányban érintett személyeket és szervezeteket.

Szponzor

Együttműködők

Nyomozók

  • Kutatásvezető: Gilbert Donders, Prof., Regional Hospital Heilig Hart, Tienen, Belgium

Publikációk és hasznos linkek

A vizsgálattal kapcsolatos információk beviteléért felelős személy önkéntesen bocsátja rendelkezésre ezeket a kiadványokat. Ezek bármiről szólhatnak, ami a tanulmányhoz kapcsolódik.

Tanulmányi rekorddátumok

Ezek a dátumok nyomon követik a ClinicalTrials.gov webhelyre benyújtott vizsgálati rekordok és összefoglaló eredmények benyújtásának folyamatát. A vizsgálati feljegyzéseket és a jelentett eredményeket a Nemzeti Orvostudományi Könyvtár (NLM) felülvizsgálja, hogy megbizonyosodjon arról, hogy megfelelnek-e az adott minőség-ellenőrzési szabványoknak, mielőtt közzéteszik őket a nyilvános weboldalon.

Tanulmány főbb dátumok

Tanulmány kezdete

2011. szeptember 1.

Elsődleges befejezés (Tényleges)

2013. április 1.

A tanulmány befejezése (Tényleges)

2013. október 1.

Tanulmányi regisztráció dátumai

Először benyújtva

2011. szeptember 27.

Először nyújtották be, amely megfelel a minőségbiztosítási kritériumoknak

2011. október 3.

Első közzététel (Becslés)

2011. október 5.

Tanulmányi rekordok frissítései

Utolsó frissítés közzétéve (Becslés)

2014. szeptember 8.

Az utolsó frissítés elküldve, amely megfelel a minőségbiztosítási kritériumoknak

2014. szeptember 5.

Utolsó ellenőrzés

2014. szeptember 1.

Több információ

Ezt az információt közvetlenül a clinicaltrials.gov webhelyről szereztük be, változtatás nélkül. Ha bármilyen kérése van vizsgálati adatainak módosítására, eltávolítására vagy frissítésére, kérjük, írjon a következő címre: register@clinicaltrials.gov. Amint a változás bevezetésre kerül a clinicaltrials.gov oldalon, ez a webhelyünkön is automatikusan frissül. .

Iratkozz fel